Replies to post #32089 on Intellipharmaceutics International Inc. (IPCI)

[illmatix0711]

WELL THERE HAS BEEN THE PRIVATE PLACEMENT OF ABOUT 4 MILLION $

i dont like this stock anymore ... anyway i wont sell !

in germany we say "hassliebe" its like "hatelove"

:D

[doogdilinger]

Nice to see the increases in Seroquel and Focalin now that the holiday season has passed.

The key number we're hoping to see dramatic improvement on as 2018 unfolds is on SeroquelXR. It's been stated here many times by several posters that they're hoping MNK can secure more contracts on SeroquelXR as 2018 unfolds and we definitely need them...otherwise there's gonna be zero chance of IPCI attaining profitability by June and avoiding another raise.

And since IPCI's not providing us with any updates whatsoever on their ongoing behind the scenes endeavors on Regabatin, their Oxy NDA candidate formerly known as Rexista or their proprietary PODRAS delivery tech platform...the chances of them securing any partners on any of them look slim(huge understatement I know lol).

Why IPCI mgmt. can't be bothered informing the market on whether or not they did in fact launch additional PODRAS studies sometime in the back half of 2017 is beyond me?

And why IPCI mgmt. continues to not bother informing the market on whether or not they've launched or are launching the required CAT 3 oral and nasal HAP studies on their OxyContin NDA candidate is beyond me as well?

And finally, IPCI mgmt. has still never bothered informing the market on why all the patent revisions were filed last year on their Regabatin NDA and what all that patent maneuvering even means for the potential R&D partnership possibilities on Regabatin?

Those are clearly the 3 most impactful potential catalysts this company currently possesses in their pipeline...but as Amigo_Mike has been saying for years...if the husband and wife team at IPCI's HQ's can't begin to even start unlocking the "potential" underlying inherent value in them...let alone be bothered providing any updated blueprints on the next steps of them even trying to initiate plans on how to start unlocking the potential inherent value in them...then institutional hands will continue to avoid this stock like the plague...and unlike the insane action PTIE was able to get on their REMOXY oral and nasal studies results...IPCI will continue suffering through the market apathy that's been constantly plaguing them since last July's Rexista AdCom failure sigh!

[doogdilinger]

PTIE 10 year chart>>>



IPCI 10 year chart>>>

[AngeloFoca]

Seroquel : as of 5th Jan - TRX Count
Mallinck 549 (previous weeks: 477 - 516 -648 -639) this is useful - also need for same weekly dates, #s in Seroquel XR $ SALES, and December 2017 monthly sales.

Focalin: as of 5th Jan - TRX Count
Par 3.97k (previous weeks: 3.65 - 4.88 -5.47 -5.73 -6.34) this is of no use... need monthly (December) sales $ only - never had that as weekly - If you provide me with the #s I'll update the spread sheet.

NOTE: Since the #s reported can't be counted on as being actual performance... we can use them only for trend lines.

HOWEVER... One encouraging thing is that since these #s don't reflect what actual sales are... then the IPCI royalty payments are apparently not the paultry %age split that the figures seemed to have suggested.

Therefore there is hope that IPCI's %age split is what I think it should be (at least 30% - possibly 40%) and IF MNK is able to capture a healthy 10% of Seroquel XR sales, then there is hope for sizeable royalty payments down the road... not only on Seroquel but Lamictal and Pristiq.